Basilard BioTech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Basilard BioTech is an early-stage biotech focused on disrupting the gene delivery bottleneck in cell and gene therapy (CGT) manufacturing. Its core innovation is the Celletto™ platform, a mechanoporation technology designed to deliver genes with high efficiency, nuclear targeting, and parallel processing while maintaining cell viability. The company is pre-revenue and positioned to enable more scalable and cost-effective production of advanced therapies, though it faces significant technical and commercial validation hurdles typical of platform technologies at this stage.

Drug Delivery

Technology Platform

Celletto™, a nanomechanical gene delivery (mechanoporation) platform designed for non-viral, high-efficiency transfection of cells for cell and gene therapy manufacturing. It features single-site poration, nuclear delivery, and massive parallelization.

Opportunities

The company addresses a critical bottleneck in the fast-growing cell and gene therapy market, where high costs and supply chain issues with viral vectors create a strong demand for efficient, scalable non-viral alternatives.

Successfully commercializing Celletto™ could position Basilard as a key enabler for next-generation therapies, capturing significant value in the CGT manufacturing tools sector.

Risk Factors

Key risks include the technical challenge of validating the platform's superiority over existing methods across diverse cell types in a scalable, GMP-ready format, and the commercial challenge of displacing the entrenched, regulatory-familiar viral vector standard in a conservative industry.

The company is also pre-revenue and reliant on external funding.

Competitive Landscape

Basilard competes in the non-viral gene delivery space, facing competition from established electroporation companies (e.g., MaxCyte, Lonza), lipid nanoparticle (LNP) developers, and other novel physical methods (e.g., acoustic poration, microfluidics). Its success hinges on demonstrating clear advantages in efficiency, viability, and nuclear delivery over these alternatives.

More companies in Drug Delivery & Formulation →More companies in United States →